Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Initial Efficacy of CM313 (SC) in Primary Immune Thrombocytopenia
NCT06594146Phase 2Active, not recruiting
- Sponsor
- Keymed Biosciences
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in primary immune thrombocytopenia (ITP), sponsored by Keymed Biosciences. Started Nov 2024; status: active, not recruiting.
02
Drugs
cm313
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06594146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594146.